Acasă › Mielom multiplu › Massachusetts › Boston
Studii clinice pentru Mielom multiplu în Boston, MA
42 studii pentru Mielom multiplu caută participanți în și în jurul orașului Boston (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
În curs de recrutareFaza 3
- Research Site, Boston
- Research Site, Boston
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 3
- Tufts Medical Center, Boston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 3
- Dana Farber Cancer Institute, Boston
- Boston University Medical Center, Boston
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
În curs de recrutareFaza 3
- Dana Farber / Harvard Cancer Center, Boston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
În curs de recrutareFaza 4
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
- Massachusetts General Hospital, Boston
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1/2
- Mass General Brigham, Boston
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
În curs de recrutareFaza 2
- Beth Israel Deaconess Medical Center, Boston
ELISA in Relapsed/Refractory MM
În curs de recrutareFaza 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
În curs de recrutareFaza 3
- Boston Medical Center, Boston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
În curs de recrutareFaza 1/2
- Dana-Farber Cancer Institute /ID# 271846, Boston
Elranatamab in R/R Multiple Myeloma
În curs de recrutareFaza 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Beth-Israel Deaconess Medical Center, Boston
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Dana Farber Cancer institution, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Massachusetts General Hospital, Boston
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
În curs de recrutareFaza 3
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
În curs de recrutareFaza 1/2
- GSK Investigational Site, Boston
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
În curs de recrutareFaza 1/2
- Research Site, Boston
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
În curs de recrutareFaza 3
- Tufts Medical Center, Boston
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
În curs de recrutareFaza 1/2
- Boston Medical Center, Boston
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
În curs de recrutareFaza 1
- Dana-Farber Cancer Institute, Boston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
În curs de recrutareFaza 1/2
- Research Site, Boston
- Research Site, Boston
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
În curs de recrutareFaza 2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Selinexor and Backbone Treatments of Multiple Myeloma Patients
În curs de recrutareFaza 1/2
- Dana Farber Cancer Institute, Boston
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
În curs de recrutareFaza 1
- Dana Farber/Harvard Cancer Center, Boston
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
În curs de recrutare
- Dana-Farber Cancer Institute, Boston
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
În curs de recrutareFaza 3
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Dana Farber Cancer Institute, Boston
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
În curs de recrutareFaza 1
- Beth Israel Deaconess Medical Center, Boston
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
În curs de recrutareFaza 1
- Dana Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
În curs de recrutare
- Massachusetts General Hospital Cancer Center, Boston
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
În curs de recrutareFaza 1
- Beth Israel Deaconess Medical Center, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
În curs de recrutareFaza 1/2
- Massachusetts General Hospital, Boston
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Dana-Farber Cancer Institute, Boston
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
În curs de recrutare
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute, Boston
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
În curs de recrutareFaza 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
În curs de recrutareFaza 1/2
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
În curs de recrutareStudiu observațional
- Boston University Cancer Research Center, Boston
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1/2
- Dana-Farber Cancer Institute, Boston
Studii pentru Mielom multiplu în alte orașe
- New York City, NY60 studii
- Atlanta, GA41 studii
- Houston, TX38 studii
- Durham, NC37 studii
- Nashville, TN32 studii
- Denver, CO27 studii
- Rochester, MN24 studii
- St. Louis, MO24 studii
- Columbus, OH24 studii
- Baldwin Park, CA23 studii
- Chicago, IL22 studii
- Seattle, WA22 studii
Alte studii în Boston
- Cancer de sân111 studii
- Cancer pulmonar cu celule non-pătrate90 studii
- Cancer (toate tipurile)86 studii
- Cancer colorectal63 studii
- Cancer metastatic63 studii
- Cancer pulmonar62 studii
- Cancer ovarian61 studii
- Cancer de prostată59 studii
- Depresie52 studii
- Cancer endometrial50 studii
- Insuficiență cardiacă44 studii
- Leucemie mieloasă acută44 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.